论文部分内容阅读
目的观察长春瑞滨(NVB)联合顺铂(PDD)治疗晚期非小细胞肺癌的疗效及其毒副反应。方法用NP方案(NVB+PDD)和EP方案(VP-16+PDD)分别治疗晚期非小细胞肺癌40例,每例患者连续化疗2个周期,比较二组患者的近期疗效和毒副反应的差别。结果NP和EP组化疗有效率(CR+PR)分别为37.5%(15/40)和27.5%(11/40),前者明显高于后者(P<0.05)。但病理类型、分期和既往治疗情况对疗效的影响2组间无显著差异(P>0.05)。骨髓抑制为主要的毒副反应,白细胞下降NP组为77.8%(31/40),EP组为62.5%(25/40),均多为轻中度下降,二者无明显差异(P>0.05)。局部静脉炎发生率NP组为45%(18/40),多为轻中度;EP组为10%(4/40),前者显著高于后者(P<0.01)。结论NVB联合PDD是晚期NSCLC的有效化疗方案,其疗效优于EP方案,毒副反应可耐受,可用于晚期NSCLS的一线治疗。
Objective To observe the curative effect and toxicity of vinblastine (NVB) combined with cisplatin (PDD) in the treatment of advanced non-small cell lung cancer. Methods 40 cases of advanced non-small cell lung cancer (NSCLC) were treated with NP regimen (NVB + PDD) and EP regimen (VP-16 + PDD) respectively. Each patient was treated with two cycles of continuous chemotherapy. difference. Results The effective rates of chemotherapy (CR + PR) in NP group and EP group were 37.5% (15/40) and 27.5% (11/40), respectively. The former was significantly higher than the latter (P <0.05). However, there was no significant difference between the two groups on pathological type, stage and past treatment (P> 0.05). Myelosuppression was the main side effect. The leukopenia was 77.8% (31/40) in the NP group and 62.5% (25/40) in the EP group, with mild to moderate decrease in both groups (P> 0.05 ). The incidence of local phlebitis in NP group was 45% (18/40), mostly mild to moderate; EP group was 10% (4/40), the former was significantly higher than the latter (P <0.01). Conclusions NVB combined with PDD is an effective chemotherapy regimen for advanced NSCLC. Its efficacy is superior to that of EP regimen. Toxicity and side effects can be tolerated. It can be used in the first-line treatment of advanced NSCLC.